Novo Nordisk lost patent protection for its semaglutide weight-loss drug in India, prompting at least five Indian drugmakers to launch generic versions priced up to 80% lower. This price war challenges Novo's market share in a crucial market with high diabetes and obesity rates. Novo has responded by cutting prices and partnering with local firms to maintain its lead. The entry of generics is expected to impact Novo's sales in India, but the company’s strong brand and distribution network may help it retain significant market share despite the competition.
The global blood glucose monitoring system market, valued at $16.8 billion in 2025, is projected to grow to $39.4 billion by 2035 at an 8.9% CAGR. Growth is fueled by rising diabetes prevalence, advancements in AI-enabled monitoring devices, and incr...
Vivani Medical is developing a semaglutide implant aimed at improving long-term adherence to GLP-1 treatments like Wegovy and Ozempic, which help with obesity and diabetes. The implant, designed to be replaced biannually or annually, could reduce sid...
